Stockscreener 앱 받기
3.085
0.16%
-0.005
시간 외 거래:
2.99
-0.095
-3.08%
전일 마감가:
$3.09
열려 있는:
$3.2
하루 거래량:
15,199
Relative Volume:
0.34
시가총액:
$3.61M
수익:
$4.96M
순이익/손실:
$-6.82M
주가수익비율:
-0.0472
EPS:
-65.4
순현금흐름:
$-6.64M
1주 성능:
+3.18%
1개월 성능:
+48.67%
6개월 성능:
-40.79%
1년 성능:
-41.55%
1일 변동 폭
$3.04
$3.20
1주일 범위
$2.8401
$3.20
52주 변동 폭
$1.72
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
명칭
Inmed Pharmaceuticals Inc
전화
(604) 669-7207
주소
1445-885 WEST GEORGIA ST., VANCOUVER
INM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
3.085 | 3.61M | 4.96M | -6.82M | -6.64M | -65.40 |
|
ZTS
Zoetis Inc
|
157.44 | 68.46B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.32 | 47.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.70 | 45.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.19 | 17.90B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.60 | 13.14B | 2.76B | 1.11B | 898.10M | 22.77 |
Inmed Pharmaceuticals Inc 주식(INM)의 최신 뉴스
SEC Form PRE 14A filed by InMed Pharmaceuticals Inc. - Quantisnow
InMed Pharmaceuticals cancels special shareholder meeting By Investing.com - Investing.com Canada
InMed Pharmaceuticals cancels special shareholder meeting - Investing.com
InMed Pharmaceuticals sets date for special shareholder meeting By Investing.com - Investing.com South Africa
InMed Pharmaceuticals sets date for special shareholder meeting - Investing.com
InMed Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com Australia
InMed Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com South Africa
InMed Pharmaceuticals : Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview - MarketScreener
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 By Investing.com - Investing.com India
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 - Investing.com India
InMed Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
InMed Pharmaceuticals Struggles with Losses Amid Revenue Decline - MSN
InMed Pharmaceuticals Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Defense World
InMed Pharmaceuticals Board Reshuffle After Director Resignation - TipRanks
InMed Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) reports earnings - Quartz
InMed Pharmaceuticals Inc. SEC 10-Q Report - TradingView
InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation - TipRanks
Inmed selects IVT formulation of INM-089 for dry AMD - BioWorld Online
InMed advances AMD treatment with promising IVT drug formulation - MSN
Revolutionary Eye Drug INM-089 Achieves 10X Therapeutic Levels in Macular Degeneration Treatment - StockTitan
Inmed Pharmaceuticals Inc (INM-Q) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals (NASDAQ: INM) Secures International Patent for Novel Compounds - Defense World
InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs - TipRanks
InMed Pharmaceuticals secures international patent - Investing.com India
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds - Newsfile
InMed Secures Breakthrough 20-Year Patent in Mexico for Novel Cannabinoid Compounds - StockTitan
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - Asianet Newsable
InMed Pharmaceuticals (NASDAQ: INM) Announces Positive Results from INM-901 Alzheimer’s Disease Study - Defense World
InMed Hails Alzheimer's Study, Stocks Shoot Higher - Baystreet.ca
InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study - TipRanks
InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study - TipRanks
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study - Newsfile
SABBY MANAGEMENT, LLC Acquires Shares in InMed Pharmaceuticals I - GuruFocus
InMed Pharmaceuticals Inc. Holds 2024 Annual General Meeting – Elects Directors and Appoints Auditor - Defense World
InMed Pharmaceuticals Director Faces Resignation After Shareholder Vote at Annual Meeting - StockTitan
InMed Announces Results of 2024 Annual General Meeting - Newsfile
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 10 million in funding - Marketscreener.com
InMed Enters Into Standby Equity Purchase Agreement - Newsfile
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Inmed Pharmaceuticals Inc (INM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.92%
자본화:
|
볼륨(24시간):